5Vote!
The Boston Business Journal (Free subscription) | 3 hours ago
Genzyme Corp. said Tuesday its approved drug for leukemia, Campath, has shown promise in a trial that combined the therapy with another drug.
5Vote!
The Boston Business Journal (Free subscription) | yesterday
Drug developer Immunogen Inc. said preliminary testing for its BT-062 cancer therapy has produced “encouraging” results that merit a new round of trials featuring a more frequent dosing regimen.
+Vote!
Medical News Today (Free subscription) | yesterday
Clavis Pharma ASA (OSE: CLAVIS) announces that positive clinical data from its Phase II study with its lead cancer product candidate elacytarabine in patients with late-stage acute myeloid leukaemia (AML) was presented at the 51st American Society of Hematology (ASH) Annual Meeting in New Orleans, LA, USA...
6Vote!
Medical News Today (Free subscription) | yesterday
A new three-drug combination has shown in a phase 1/2 clinical trial that it is a "highly effective regimen" in the treatment of patients newly diagnosed with multiple myeloma, a cancer of white blood cells in bone marrow, say researchers from Dana-Farber Cancer Institute...
+Vote!
Medical News Today (Free subscription) | yesterday
More than 15 million Americans are recruited annually to participate in clinical trials according to the Alliance for Human Research Protection (AHRP), and most will be compensated for their participation. Research institutions view payments to volunteers as compensation for time and expenses; not as compensation for potential risks related to participating in the experiments...
3Vote!
Medical News Today (Free subscription) | 12/05/2009
Officials at the new Muhammad Ali Parkinson Center at Barrow Neurological Institute announced today the center's participation in a novel Parkinson's study aimed at determining the physical and neurological impact of simple exercise on Parkinson's patients...
3Vote!
BBC News (Free subscription) | 12/04/2009
Police and the Crown Prosecution Service defend their decision to prosecute nine men who were all cleared after a 10-month drugs trial.
3Vote!
Medical News Today (Free subscription) | 12/03/2009
In a commentary published in the December 2, 2009 issue of the Journal of the American Medical Association, Charles H. Hennekens, M.D., the first Sir Richard Doll Research Professor in the Charles E...
3Vote!
Medical News Today (Free subscription) | 12/03/2009
Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, announced preliminary data for the company's PH-10 Phase 2 clinical trial for Psoriasis as well as for its Phase 2 clinical trial for Atopic Dermatitis. Dr. Craig Dees, Ph.D...
3Vote!
Newsday (Free subscription) | 12/03/2009
The trial of a man charged with trafficking over 500 kilos of marijuana in 2002, which is being heard before the Port-of-Spain Sixth Criminal Court, was yesterday convened on a beach on the north coast where four witnesses testified.
3Vote!
Medical News Today (Free subscription) | 12/02/2009
OptiNose is pleased to announce the publication of results from its Phase II clinical study investigating the efficacy and tolerability of its novel, intranasal drug/device product for the topical treatment of chronic rhinosinusitis with nasal polyps in Rhinology, the official journal of the International and European Rhinologic Societies...
6Vote!
Medical News Today (Free subscription) | 12/02/2009
A small study of middle-aged women finds that "guilt-ridden dieters," impulsive eaters and those too busy to focus on food are the most likely to show signs of obesity. Half of women fit into two other categories, the study says, and were found to be the least likely to be leaning toward fat. Both types of women in those groups are concerned about nutrition and like to eat healthy...
3Vote!
Medical News Today (Free subscription) | 12/02/2009
Multiple-ligament knee injuries resulting from traumatic knee dislocations such as high impact car accidents or certain sports are uncommon, and the optimal timing of surgical repair or reconstruction has not been definitively established...
3Vote!
Medical News Today (Free subscription) | 12/02/2009
Agennix AG (FRANKFURT: AGX) (XETRA: AGX) reported results from the talactoferrin randomized, double-blind, placebo-controlled Phase 2 trial in severe sepsis. The trial evaluated talactoferrin versus placebo in 190 adult patients with severe sepsis enrolled at 25 leading centers across the U.S...
3Vote!
Medical News Today (Free subscription) | 12/02/2009
Pacira Pharmaceuticals, Inc., announced that its second Phase III placebo controlled study of EXPAREL(TM) (DepoBupivacaine) met its primary endpoint...